Welcome
Login and fund life
HairClone is a startup biotechnology company focused on developing personalised treatments using the patient’s own cultured hair cells to rejuvenate their thinning hair. Step one of this process which involves banking a patient's hair follicles will be launched in 2018.
HairClone
Discovery, idea
Hairloss (androgenic alopecia)
300.000£
This is the investment proposal of HairClone
3000000
9.09%
Why Capital Cell invests in this company?
HairClone has developed new technology to...
HairClone will capture a large $4bn market. With their rejuvenation arm of the business they could potentially even grow this market by attracting a whole new set of customers.
Furthermore, biobanking of hair cells early on increases the likelyhood of future hair rejuvenation/regeneration and will build continuous revenues
Investment risk
...
HairClone is a regenerative medicine company developing two personalised therapies using the patient's own cultured hair cells to treat androgenic alopecia in men and women. It was founded by a group of leading scientists, clinicians and biotechnologist with proven track record in developing commercial cell therapies that have treated about 1 million patients. The lead treatment aims to rejuvenate thinning hairs for patients when they first notice hair loss, the second treatment aims to regenerate brand new hair follicles for patients with extensive hair loss. These treatments could dramatically revolutionise the market by filling the unmet needs of women with female pattern baldness, men for whom it is too early in the balding process for hair transplantation to be recommended and patients who need greater coverage than can be achieved by transplantation. In 2018 HairClone will launch the world's first hair follicle banking service which will allow patients to store a small number of hair follicles for future expansion. We are collaborating with leading scientists to develop systems that expand hair follicle cells in culture and maintain their follicle inducing potential. We have an expanding clinical partner network of leading hair transplant surgeons around the world who are providing non dilutive co-funding and a deep clinical know how and expertise, linking us to patients for both banking and later treatment.
Our team
The team have been founders, CEOs and Directors at multiple Public and Private Biotechs in the US, EU and UK. We have developed cell based products that have treated approx. one million people and our Medical Directors have performed over 7,000 hair transplants. We have extensive clinical and regulatory experience and have been involved in the design and operation of over 20 clinical trials around the world including the world's first trial using cultured hair follicle cells.
Founders
Paul is a founding Director of HairClone. He has over 25 years’ experience in the development and commercialisation of Regenerative Medicine and Cell Therapy products that have treated over half a million people. Previously he has held Executive Board level positions in both public and private Companies in the UK and US.
Vincent has more than 28 years of experience of applied research and product development in the fields of regenerative medicine, wound healing and cosmetics. He has worked in six different companies (Organogenesis, L’Oreal, Smith and Nephew) located in Europe, United States and Asia. He is currently Scientific Director of Hairclone (UK) and Chief Innovation Officer at Cutiss AG (Switzerland).
Qualified from the Royal College of Surgeons in Ireland and co-founded the Farjo Hair Institute in 1993 exclusively offering hair transplant surgery and hair restoration medicine. Dr Farjo is a Past President of both British Association of Hair Restoration Surgery and International Society of Hair Restoration Surgery. He is a diplomate of American Board of Hair Restoration Surgery, Past Medical Director of Institute of Trichologists and member of European Hair Research Society
Nilofer Farjo has been performing hair transplants for 25 years and is recognised for her educational and leadership contributions at international congresses and meetings. She also has been acknowledged by her peers for outstanding achievement in basic science or clinically-related research in hair pathophysiology or anatomy as it relates to hair restoration for which she was awarded the ISHRS Platinum Award in 2012. Nilofer currently works on hair biology research with six UK Universities.
Eric is a erial entrepreneur who has raised nearly €90 million over the course of his career and has had numerous successes in the sale and initial public offering of biotechnology companies. He is co-founder of four biotechnology called Myosix, Murigenetics, HairClone and Digital Orthopaedics. Eric is as well Board member of the biotechnology company Bioxodes, VitriCell and Innobiochips. He was principal of the life sciences practice of Arthur D. Little in Paris and Boston.
Key Members
Advisors
Join now to see the rest of HairClone’s pitch.
Let's invest
HairClone will be open for investment soon.
Make a reservation with no compromise, just enter the amount you would like to invest.
If you’re interested in joining this round, please tell us how much you’d like to invest, then click “I AM INTERESTED”
Once the campaign is live, you will have 5 days to formalise your investment and make the payment; until then you are free to cancel this reservation at any time
If you choose to continue to make this pledged investment when the campaign opens, you should be aware that your capital would be at risk. Please read our Risk Warning for further details of the risks involved with early stage investing.
Insert a widget in your web page
Share this project in your website. Copy and paste the following code in your content
Copied!
Preview